Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, Denmark, 10 March 2026 – NMD Pharma A/S, a...
-
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data...
-
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data...
-
Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with...
-
Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with...
-
Aarhus, Denmark, 6 January 2026 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today...
-
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research,...
-
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research,...
-
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA...
-
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA...